New hope for recurrent endometrial cancer: personalized combo therapy tested
NCT ID NCT04486352
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining targeted drugs with the immunotherapy atezolizumab can shrink tumors or slow cancer growth in people with endometrial cancer that has come back or persists. About 148 participants whose cancer has progressed after at least one prior treatment will receive therapy matched to their tumor's genetic markers. The goal is to improve response rates and delay progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atlantic Health Systems/Morristown Medical Center
ACTIVE_NOT_RECRUITINGMorristown, New Jersey, 07960, United States
-
Baptist Memorial Hospital
WITHDRAWNMemphis, Tennessee, 38120, United States
-
City of Hope Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGDuarte, California, 91010, United States
-
Dana Farber Cancer Institute
ACTIVE_NOT_RECRUITINGBoston, Massachusetts, 02125, United States
-
Duke University Cancer Center
ACTIVE_NOT_RECRUITINGDurham, North Carolina, 27710, United States
-
Englewood Health
ACTIVE_NOT_RECRUITINGEnglewood, New Jersey, 07631, United States
-
Lifespan - Rhode Island Hospital
ACTIVE_NOT_RECRUITINGProvidence, Rhode Island, 02903, United States
-
Maine Medical Center
ACTIVE_NOT_RECRUITINGScarborough, Maine, 04074, United States
-
Medstar Georgetown Cancer Institute
ACTIVE_NOT_RECRUITINGWashington D.C., District of Columbia, 20007, United States
-
Mount Sinai Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGMiami Beach, Florida, 33140, United States
-
Nebraska Methodist Hospital
ACTIVE_NOT_RECRUITINGOmaha, Nebraska, 68114, United States
-
Providence Portland Cancer Institute
ACTIVE_NOT_RECRUITINGPortland, Oregon, 97213, United States
-
Roswell Park
ACTIVE_NOT_RECRUITINGBuffalo, New York, 14263, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
ACTIVE_NOT_RECRUITINGSan Francisco, California, 94143, United States
-
University of Chicago
ACTIVE_NOT_RECRUITINGChicago, Illinois, 60637, United States
-
University of Kansas Cancer Center
ACTIVE_NOT_RECRUITINGWestwood, Kansas, 66205, United States
-
University of Minnesota
ACTIVE_NOT_RECRUITINGMinneapolis, Minnesota, 55455, United States
-
University of Oklahoma Health Stephenson Cancer Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
University of Pittsburgh Medical Center
ACTIVE_NOT_RECRUITINGPittsburgh, Pennsylvania, 15261, United States
-
Washington University School of Medicine Siteman Cancer Center
WITHDRAWNSt Louis, Missouri, 63110, United States
-
Weill Cornell Medicine
ACTIVE_NOT_RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Could gentle yoga and breathing ease Cancer's lingering toll?